TopDollar Investing

[Slimer84]

Medisafe 1 Technologies Enters Discussions to Launch Pilot Project in Major Jerusalem Hospital
Nov. 29, 2010 (PR Newswire) --

JERUSALEM, November 29, 2010 /PRNewswire-FirstCall/ -- Medisafe 1 Technologies Corp. (OTCBB: MFTH), a developer of patented technologies that physically prevent unauthorized administration of prescription medications, announced today that the company has engaged in preliminary discussions to launch a pilot of its syringe locking device, with a major hospital in Jerusalem.

The discussions are focusing on implementing the technology in one of the hospital's internal departments. The target date for launching the pilot program is within the next six months.

The pilot will demonstrate the effectiveness of the device to physically block the administration of incorrect medications or dosages to patients in the department.

The technology features a barcode reader that confirms both the medication and its intended patient. If the system does not verify the correct dosage and patient, the locking device on the syringe will not open and enable administration.

"We are optimistic about the early discussions with a very well-respected department in one of the region's best hospitals," said Jacob Elhadad, CEO of Medisafe 1 Technologies. "The successful implementation of this pilot could potentially lead to more widespread demand for our technology."

"The number of deaths caused around the world by the human error in the administration of improper medicines or dosages in hospitals is staggering. The cost of human life, and the cost of medical malpractice suits far outweigh the costs of implementing better technology," Elhadad added.

About Medisafe 1 Technologies

Medisafe 1 Technologies seeks to effectively prevent unauthorized administration of a drug or medicinal substance by hypodermic needle. Medisafe's patented technology is a medical assembly with a locking mechanism that is intended to ensure the substance cannot be released from the hypodermic needle without positive pre-matching between the substance and its intended patient.

Forward-Looking Statements

This letter contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 as amended and Section 21E of the Securities Exchange Act of 1934 as amended. All forward-looking statements are inherently uncertain, based on current expectations and assumptions concerning future events or future performance of Medisafe 1 Technologies Corp., and its technologies. In evaluating such statements, prospective investors should review carefully various risks and uncertainties identified in this release, as actual results may differ materially from those indicated. Medisafe 1 Technologies Corp. public filings may be viewed at http://www.sec.gov.

Contact:
Jacob Elhadad
CEO
[phone]
[e-mail]

SOURCE Medisafe 1 Technologies Corp.


Source: PR Newswire (November 29, 2010 - 7:00 AM EST)

News by QuoteMedia
www.quotemedia.com